In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Dyne Therapeutics (DYN – Research Report), with a price ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Dyne Therapeutics (DYN – Research Report) today and set a price target of ...

A woman is airing her dirty laundry about her boyfriend on TikTok. An Australian woman called out her partner for the way he ...

Stock analysts at BMO Capital Markets started coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a ...

Fintel reports that on March 12, 2025, BMO Capital initiated coverage of Dyne Therapeutics (NasdaqGS:DYN) with a Outperform ...

MILES NELEN, Cooperstown basketball: Class C boys sectional tournament most valuable player scored 35 points in title game, ...

The series features more aggressive equity allocations further away from retirement than peers. Its glide path starts at 99% equity and stays above the average peer until 10 years from retirement ...

In celebration of Saturday’s Australian Club Championship showdown between Brothers and Easterm Suburbs at Crosby Park, we ...

After hours: March 14 at 5:10:19 PM EDT Loading Chart for DYN ...